Company / Total Assets
ENANTA PHARMACEUTICALS INC Total Assets History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$280.7M
FY2025
5-year range
$280.7M / $462.3M
FY2021-FY2025
Trend
-25.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Total Assets has fluctuated over the past 10 years, ranging from $281M in FY2025 to $490M in FY2019.
Based on SEC 10-K filings.
$281M in FY2025 with a 5-year CAGR of -10.4%.
Declined from $462M to $281M over the past 2 years.
Total Assets over time
Growth rates
- 3-Year CAGR
- -9.2%
- 5-Year CAGR
- -10.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -10.4%, indicating a declining trend.
- In FY2025, total assets decreased 25.5% year-over-year.
- Peak total assets was recorded in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $280.7M | -25.5% |
| FY2024 | $376.7M | -18.5% |
| FY2023 | $462.3M | +23.1% |
| FY2022 | $375.4M | -14.4% |
| FY2021 | $438.8M | -9.7% |
| FY2020 | $486.1M | -0.8% |
| FY2019 | $489.8M | +18.3% |
| FY2018 | $414.2M | +26.8% |
| FY2017 | $326.6M | +16.1% |
| FY2016 | $281.3M | +14.3% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026